Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepzelca in advanced gastrointestinal malignancies with DNA repair mutations
NCT05229588Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in gastrointestinal malignancy, sponsored by HonorHealth Research Institute. Started Jun 2022; status: completed.
02
Drugs
lurbinectedin
03
Conditions
gastrointestinal malignancy
Beyond the preview
Go deeper on NCT05229588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229588.